ArticleOncotarget2018

Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy.

Anne Bordron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.